Physician profile
Michael Papsidero
NPI 1891826764
$1,042.54
in general payments reported to CMS, 2019-2025
24 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $39.71 · 2021: $84.06 · 2022: $129 · 2023: $160 · 2024: $234 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $110.45 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $104.06 | 2023-2025 | Mounjaro, Zepbound |
| Genzyme Corporation | $101.41 | 2019-2023 | |
| Corcept Therapeutics | $77.38 | 2021-2025 | Korlym |
| Amgen INC. | $76.59 | 2024-2025 | Evenity, Prolia, Tezspire |
| Novo Nordisk INC | $57.22 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $49.82 | 2025 | Yorvipath |
| Acclarent, INC | $48.50 | 2019 | |
| Abbott Laboratories | $47.60 | 2024-2025 | Proclaim, Eterna |
| Smith+Nephew, INC. | $45.04 | 2020-2025 | |
| Medtronic, INC. | $42.37 | 2024-2025 | Minimed 780g |
| Karl Storz Endoscopy-America | $34.16 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $32.41 | 2023 | |
| Grt US Holding, INC. | $27.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.51 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $22.26 | 2019 | |
| Antares Pharma, INC. | $20.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.94 | 2019 | |
| Clarus Therapeutics INC. | $19.64 | 2021 | |
| Genentech USA, INC. | $19.56 | 2025 | Xolair |
| Optinose US, INC. | $19.22 | 2024 | |
| Rayner Intraocular Lenses Limited | $18.97 | 2022 | |
| Ascensia Diabetes Care US INC. | $14.10 | 2024 | |
| Insulet Corporation | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Papsidero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.